2024
Spesolimab increases the percentage of generalized pustular psoriasis (GPP) patients with clear skin over time as measured by the Physician’s Global Assessment for GPP (GPPGA): Results from the EFFISAYIL® 2 trial
Gottlieb A, Strober B, Merola J, Mostaghimi A, Farberg A, Guercio J, Tang M, Thoma C, Lebwohl M. Spesolimab increases the percentage of generalized pustular psoriasis (GPP) patients with clear skin over time as measured by the Physician’s Global Assessment for GPP (GPPGA): Results from the EFFISAYIL® 2 trial. SKIN The Journal Of Cutaneous Medicine 2024, 8: s490. DOI: 10.25251/skin.8.supp.490.Peer-Reviewed Original ResearchGeneralized pustular psoriasisPhysician global assessmentSkin symptomsPustular psoriasisGlobal assessmentProportion of patientsPercentage of patientsTreating generalized pustular psoriasisLife-threatening skin diseaseSignificant patient burdenYears of ageDosing regimenPediatric patientsClear skinSpesolimabPatientsContinuous treatmentMonoclonal antibodiesSkin diseasesPatient burdenSymptomsPsoriasisTotal scoreSkinTreatment
2008
Substantial Alterations of the Cutaneous Bacterial Biota in Psoriatic Lesions
Gao Z, Tseng C, Strober B, Pei Z, Blaser M. Substantial Alterations of the Cutaneous Bacterial Biota in Psoriatic Lesions. PLOS ONE 2008, 3: e2719. PMID: 18648509, PMCID: PMC2447873, DOI: 10.1371/journal.pone.0002719.Peer-Reviewed Original ResearchConceptsPsoriatic lesionsHealthy personsIdiopathic inflammatory disorderNormal skin samplesBroad-range PCRPsoriatic patientsInflammatory disordersUninvolved skinPsoriatic skinCutaneous samplesNormal skinPatientsLesion samplesNormal personsSubstantial alterationsLesionsPropionibacterium speciesSkin samplesPsoriasisSkinSpecies-level operational taxonomic unitsRDNA PCRAlterationsExtracted DNARange PCR